Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Michael D Jain, PhD MD, Lee Mozessohn, MD, Lauren M Gerard, MD, Jackie Ostro, MD, Mansoor Radwi, MD, Bertrand Routy, MD, Bethany Gill, BSc, MMath, Tony Panzarella, M.Sc., P.Stat., Peter Anglin, MD, Matthew C Cheung, Vishal Kukreti, Lisa Hicks, MD MSc

Blood (2014) 124 (21): 2651.

https://doi.org/10.1182/blood.V124.21.2651.2651

Published: 2014

Journal Articles

HIV-Associated Diffuse Large B Cell Lymphoma: Determinants of Survival In the Era of Rituximab and HAART.

Lisa Hicks, MD, MSc, FRCPC, Matthew Cheung, MD, MS, FRCPC, Jordana Boro, Hatoon Ezzat, MBBS, FRCP, Heather Leitch, MD, PhD, FRCPC

Blood (2010) 116 (21): 2835.

https://doi.org/10.1182/blood.V116.21.2835.2835

Published: 2010

Journal Articles

Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis.

Anca Prica, MD, Kelvin K Chan, MD, Lisa Hicks, MD, MSc, Matthew Cheung, MD

Blood (2010) 116 (21): 1504.

https://doi.org/10.1182/blood.V116.21.1504.1504

Published: 2010

Journal Articles

The Role of ABO Blood Group In TTP Prevalence and Disease Outcome

Katerina Pavenski, MD, FRCP, Jordana Boro, John J. Freedman, MD, FRCPC, Marie B. Garvey, MD, Jerome M. Teitel, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC

Blood (2010) 116 (21): 4671.

https://doi.org/10.1182/blood.V116.21.4671.4671

Published: 2010

Journal Articles

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Sita Bhella, MD, Neil L Berinstein, MD, FRCPC, Nancy Pennell, BSc, Matthew Cheung, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, Violet Miliken, Marciano D. Reis, MD, FRCPC, Alden Chesney, MD, FRCPC, David Good, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC

Blood (2010) 116 (21): 1357.

https://doi.org/10.1182/blood.V116.21.1357.1357

Published: 2010

NARROW

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

HIV-Associated Diffuse Large B Cell Lymphoma: Determinants of Survival In the Era of Rituximab and HAART.

Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis.

The Role of ABO Blood Group In TTP Prevalence and Disease Outcome

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Email alerts

ASH Publications

American Society of Hematology

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

HIV-Associated Diffuse Large B Cell Lymphoma: Determinants of Survival In the Era of Rituximab and HAART.

Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis.

The Role of ABO Blood Group In TTP Prevalence and Disease Outcome

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only